Qimiao Hu Selected Research

prostaglandin-inositol cyclic phosphate

1/2022	Electroacupuncture Ameliorates Mechanical Allodynia of a Rat Model of CRPS-I via Suppressing NLRP3 Inflammasome Activation in Spinal Cord Dorsal Horn Neurons.
1/2022	Nrf2 Activation Mediates Antiallodynic Effect of Electroacupuncture on a Rat Model of Complex Regional Pain Syndrome Type-I through Reducing Local Oxidative Stress and Inflammation.
9/2020	Electroacupuncture Alleviates Mechanical Allodynia in a Rat Model of Complex Regional Pain Syndrome Type-I via Suppressing Spinal CXCL12/CXCR4 Signaling.
5/2020	Expression profiling of spinal cord dorsal horn in a rat model of complex regional pain syndrome type-I uncovers potential mechanisms mediating pain and neuroinflammation responses.
1/2020	Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats.
1/2019	TRPV1 Channel Contributes to the Behavioral Hypersensitivity in a Rat Model of Complex Regional Pain Syndrome Type 1.
1/2019	Transcriptome profiling of dorsal root ganglia in a rat model of complex regional pain syndrome type-I reveals potential mechanisms involved in pain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qimiao Hu Research Topics

Disease

8	Pain (Aches) 01/2022 - 01/2019
5	Hyperalgesia 01/2022 - 01/2019
3	Inflammation (Inflammations) 01/2022 - 05/2020
3	Ischemia 01/2020 - 01/2019
2	Reflex Sympathetic Dystrophy (Reflex Sympathetic Dystrophy Syndrome) 01/2022 - 09/2020
2	Chronic Pain 01/2022 - 01/2022
2	Hypersensitivity (Allergy) 01/2020 - 01/2019
2	Neuralgia (Stump Neuralgia) 01/2019 - 04/2017
1	Postoperative Pain 01/2022
1	Neuroinflammatory Diseases 01/2022
1	Hyperemia 01/2020
1	Edema (Dropsy) 01/2020
1	Hyperthermia 01/2019
1	Allergic Rhinitis 11/2017
1	Blister (Bulla) 11/2017

Drug/Important Bio-Agent (IBA)

7	prostaglandin-inositol cyclic phosphateIBA 01/2022 - 01/2019
2	InflammasomesIBA 01/2022 - 05/2020
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2019
2	Analgesics (Analgesic Drugs)IBA 09/2020 - 04/2017
1	Cysteine (L-Cysteine)FDA Link 01/2022
1	AntioxidantsIBA 01/2022
1	LigandsIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 09/2020
1	Capsaicin (Zostrix)FDA Link 01/2020
1	LipopolysaccharidesIBA 01/2019
1	CationsIBA 01/2019
1	CytokinesIBA 01/2019
1	3- (4- t- butylphenyl)- N- (2,3- dihydrobenzo(b)(1,4)dioxin- 6- yl)acrylamideIBA 01/2019
1	immune RNA (I-RNA)IBA 01/2019
1	Ointments (Pastes)IBA 11/2017
1	Therapeutic UsesIBA 11/2017
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 04/2017

Therapy/Procedure

4	Electroacupuncture 01/2022 - 04/2017
4	Therapeutics 01/2022 - 11/2017
1	Physical Therapy Modalities (Physical Therapy Technique) 01/2022
1	Anesthesia 01/2020
1	Acupuncture Points (Acupuncture Point) 11/2017